Cultured human airway smooth muscle cells stimulated by interleukin-1beta enhance eosinophil survival.

Airway smooth muscle may be an important cellular source of proinflammatory mediators and cytokines and may participate directly in airway inflammation. In this study we have examined whether airway smooth muscle cells could contribute to mechanisms of eosinophil accumulation by prolonging their survival. To investigate this possibility, conditioned medium from human airway smooth muscle cells stimulated with interleukin (IL)-1beta was examined on the in vitro survival of highly purified human peripheral blood eosinophils. After 7 d, when cultured in control medium, less than 1 +/- 0.2% of the initial eosinophil population remained viable. In contrast, culture in medium conditioned for 96 h by human airway smooth muscle cells stimulated with IL-1beta (1 pg-100 ng/ml) resulted in a concentration-dependent increase in eosinophil survival. (The concentration that produced 50% of this effect was 0.03 ng/ml IL-1beta.) Maximum eosinophil survival occurred at 1 to 3 ng/ml IL-1beta. This effect was also time-dependent and was readily detected in airway smooth muscle cell-conditioned medium after just 3 h of stimulation with IL-1beta (1 ng/ml). It continued to increase before reaching a plateau around 24 h, with no decrease in activity for up to 120 h of stimulation. Conditioned medium from unstimulated airway smooth muscle cells did not enhance eosinophil survival. The survival-enhancing activity was completely inhibited (the concentration that inhibited 50% [IC50] was 6.9 microg/ml) by a polyclonal goat antihuman antibody to granulocyte-macrophage colony stimulating factor (GM-CSF) (0.3-100 microg/ml), but antibodies (10-100 microg/ml) to IL-3 and IL-5, and a normal goat immunoglobulin G control had no effect on the eosinophil survival-enhancing activity. GM-CSF levels in culture medium from smooth muscle cells were markedly increased by IL-1beta and were maximum at 30 ng/ml (0.037 ng/ml/10(6) cells versus 3.561 ng/ml/10(6) cells, unstimulated versus 30 ng/ml IL-1beta). The IL-1 receptor antagonist inhibited both the production of GM-CSF (IC50 19. 1 ng/ml) and the eosinophil survival-enhancing (IC50 53.7 ng/ml) activity stimulated by IL-1beta. Release of GM-CSF elicited by IL-1beta was inhibited by dexamethasone but not by indomethacin. These data indicate that cultured human airway smooth muscle cells stimulated with IL-1beta support eosinophil survival through production of GM-CSF and thus may contribute to the local control of inflammatory cell accumulation in the airways.

[1]  K. Chung,et al.  Expression and release of interleukin-8 by human airway smooth muscle cells: inhibition by Th-2 cytokines and corticosteroids. , 1998, American journal of respiratory cell and molecular biology.

[2]  S. Johnson,et al.  Synthetic functions of airway smooth muscle in asthma. , 1997, Trends in pharmacological sciences.

[3]  J. Hogg,et al.  Inflammation of small airways in asthma. , 1997, The Journal of allergy and clinical immunology.

[4]  P. O'Byrne,et al.  Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. , 1997, American journal of respiratory cell and molecular biology.

[5]  A. Knox,et al.  Effect of interleukin‐1β, tumour necrosis factor‐α and interferon‐γ on the induction of cyclo‐oxygenase‐2 in cultured human airway smooth muscle cells , 1997 .

[6]  A. Stewart,et al.  β2‐Adrenoceptor agonist‐mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of β2‐adrenoceptor stimulation , 1997 .

[7]  K. Chung,et al.  Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. , 1997, Journal of immunology.

[8]  M. Yacoub,et al.  Release of granulocyte‐macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone , 1997, British journal of pharmacology.

[9]  M. Yacoub,et al.  Induction of cyclo‐oxygenase‐2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type , 1997, British journal of pharmacology.

[10]  E. Gopez,et al.  Pleural effusion due to herpes simplex type II infection in an immunocompromised host. , 1997, American journal of respiratory and critical care medicine.

[11]  A. Sousa,et al.  Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. , 1996, American journal of respiratory and critical care medicine.

[12]  W. Roche,et al.  Cell cultures from bronchial subepithelial myofibroblasts enhance eosinophil survival in vitro. , 1996, The European respiratory journal.

[13]  A. J. Wilson,et al.  Eosinophil apoptosis and the resolution of airway inflammation in asthma. , 1996, American journal of respiratory and critical care medicine.

[14]  Hirst Sj.  Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. , 1996 .

[15]  P. Barnes,et al.  PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. , 1996, The American journal of physiology.

[16]  W Newman,et al.  Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. , 1996, The Journal of clinical investigation.

[17]  P. Barnes,et al.  Cyclic AMP‐elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM‐CSF , 1996, British journal of pharmacology.

[18]  S. Hirst,et al.  Airway smooth muscle cell culture: application to studies of airway wall remodelling and phenotype plasticity in asthma. , 1996, The European respiratory journal.

[19]  K. Ohta,et al.  Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. , 1995, American journal of respiratory and critical care medicine.

[20]  G. Randolph,et al.  Chemokines and tissue injury. , 1995, The American journal of pathology.

[21]  J. Bousquet,et al.  Airways remodelling in asthma: no doubt, no more? , 1995, International archives of allergy and immunology.

[22]  A. Halayko,et al.  Potential role for phenotypic modulation of bronchial smooth muscle cells in chronic asthma. , 1994, Canadian journal of physiology and pharmacology.

[23]  A. Warley,et al.  Preparation of cultured airway smooth muscle for study of intracellular element concentrations by X‐ray microanalysis: Comparison of whole cells with cryosections , 1994, Journal of microscopy.

[24]  J. Campbell,et al.  Culture techniques and their applications to studies of vascular smooth muscle. , 1993, Clinical science.

[25]  S. Durham,et al.  Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. , 1993, The Journal of allergy and clinical immunology.

[26]  A. Sousa,et al.  Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. , 1993, The American review of respiratory disease.

[27]  L. Koenderman,et al.  Upregulation of formyl-peptide and interleukin-8-induced eosinophil chemotaxis in patients with allergic asthma. , 1993, The Journal of allergy and clinical immunology.

[28]  J. Hamilton,et al.  Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. , 1993, Atherosclerosis.

[29]  C. Dinarello,et al.  The role of interleukin-1 in disease. , 1993, The New England journal of medicine.

[30]  W. Arend.  Interleukin-1 receptor antagonist. , 1993, Advances in immunology.

[31]  P. Barnes,et al.  Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet-derived growth factor. , 1992, American journal of respiratory cell and molecular biology.

[32]  C. Haslett.  Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. , 1992, Clinical science.

[33]  W. R. Beam,et al.  Detection of alveolar macrophage-derived IL-1 beta in asthma. Inhibition with corticosteroids. , 1992, Journal of immunology.

[34]  S. Mattoli,et al.  Cytokine mRNA profile and cell activation in bronchoalveolar lavage fluid from nonatopic patients with symptomatic asthma. , 1992, Chest.

[35]  D. Broide,et al.  Cytokines in symptomatic asthma airways. , 1992, The Journal of allergy and clinical immunology.

[36]  J. Bousquet,et al.  Immunohistochemical characterization of the cellular infiltration in asthmatic bronchi. , 1992, The American review of respiratory disease.

[37]  P. Jeffery.  Pathology of asthma. , 1992, British medical bulletin.

[38]  K. Blaser,et al.  An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. , 1991, Journal of immunological methods.

[39]  W. Owen,et al.  Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. , 1991, The Journal of clinical investigation.

[40]  T. Lee,et al.  Identification of the major activity derived from cultured human peripheral blood mononuclear cells, which enhances eosinophil viability, as granulocyte macrophage colony-stimulating factor (GM-CSF). , 1991, The Journal of allergy and clinical immunology.

[41]  J. McDonald,et al.  The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. , 1991, The American journal of pathology.

[42]  L. Allegra,et al.  Cellular and biochemical characteristics of bronchoalveolar lavage fluid in symptomatic nonallergic asthma. , 1991, The Journal of allergy and clinical immunology.

[43]  S. Durham,et al.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.

[44]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[45]  J. Pujol,et al.  Interleukin-1 release by alveolar macrophages in asthmatic patients and healthy subjects. , 1990, International archives of allergy and applied immunology.

[46]  J. Pujol,et al.  Identification of an alveolar macrophage-derived activity in bronchial asthma that enhances leukotriene C4 generation by human eosinophils stimulated by ionophore A23187 as a granulocyte-macrophage colony-stimulating factor. , 1989, The American review of respiratory disease.

[47]  M. Jordana,et al.  Human lung fibroblast-derived granulocyte-macrophage colony stimulating factor (GM-CSF) mediates eosinophil survival in vitro. , 1989, American journal of respiratory cell and molecular biology.

[48]  W. Owen,et al.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.

[49]  P. Paré,et al.  The mechanics of airway narrowing in asthma. , 1989, The American review of respiratory disease.

[50]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[51]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.